News & Updates
Showing Multidisciplinary articles
Showing
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.
LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC
The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.
Rheumatologists need to match patient’s health literacy, says study
Communication between physicians and patients with systemic lupus erythematosus (SLE) leaves a lot to be desired, with a recent study suggesting that rheumatologists must beef up communication to match the health literacy (HL) of their patients. Doing so may foster trust and improve self-management and outcomes in SLE.
Dupilumab cuts exacerbations, improves lung function in paediatric asthma patients with high eosinophils
In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.
